Antibody Drug Conjugates (ADCs) are revolutionizing cancer treatment—but peripheral neuropathy remains a major hurdle in their development. In this on-demand webinar, Dr. Rakesh Dixit, President & CEO of Bionavigen and former Vice President of R&D, explores the urgent need for more predictive, human-relevant assays in ADC research.
Traditional preclinical models often fall short in identifying neurotoxicity risks. Dr. Dixit walks us through the evolution of ADCs and reveals why next-generation assay systems are essential for accurately modeling and mitigating peripheral neuropathy.
Presented by Rakesh Dixit, PhD, DABT, President & CEO, Bionavigen
